Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1163120 Target Snapshot

Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma · SINGLE PROTEIN · Homo sapiens

387Compounds
121Assays
2Approved Drugs
160.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt O75747. Use UniProt O75747 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O75747 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma as ChEMBL target CHEMBL1163120, mapped to UniProt O75747. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1163120
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O75747
Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma is the right protein anchor across sources, using UniProt O75747 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPhosphatidylinositol 3-kinase C2 domain-containing subunit gamma
UniProt AccessionO75747
Component TypeProtein
Sequence Length1486 aa

Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma, mapped to UniProt O75747. Sequence length is 1486 aa.

Mapped IDO75747
Review namePhosphatidylinositol 3-kinase C2 domain-containing subunit gamma
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase III
3
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC5074.0
KD86.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3942643 8.7 IC50 2.0 Preclinical
CHEMBL3959351 8.7 IC50 2.0 Preclinical
CHEMBL3979343 8.7 IC50 2.0 Preclinical
CHEMBL230011 8.49 Kd 3.2 Clinical
CHEMBL3904942 8.4 IC50 4.0 Preclinical
CHEMBL3889977 7.7 IC50 20.0 Preclinical
CHEMBL3898901 7.53 IC50 29.3 Preclinical
CHEMBL3950648 7.52 IC50 30.0 Preclinical
CHEMBL3907932 7.41 IC50 39.0 Preclinical
CHEMBL1474834 7.4 Kd 40.0 Preclinical
Distribution

pChEMBL Value Distribution

11
5.0
2
5.5
9
6.0
7
6.5
9
7.0
3
7.5
2
8.0
3
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
Assay Landscape

Assay Landscape

121
Total Assays
59
Tested Compounds
1
Assay Types
Binding — 121 assays, 59 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 93 56 6.3
assay format 20 1 5.2
cell-based format 8 2 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine